Rivaroxaban

TargetMol
Product Code: TAR-T1184
Supplier: TargetMol
CodeSizePrice
TAR-T1184-2mg2mg£99.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1184-5mg5mg£113.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1184-1mL1 mL * 10 mM (in DMSO)£116.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1184-10mg10mg£128.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1184-25mg25mg£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1184-50mg50mg£167.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1184-100mg100mg£222.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1184-200mg200mg£307.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Rivaroxaban is an orally bioavailable oxazolidinone derivative and direct inhibitor of the coagulation factor Xa with anticoagulant activity. Upon oral administration, rivaroxaban selectively binds to both free factor Xa and factor Xa bound in the prothrombinase complex. This interferes with the conversion of prothrombin (factor II) to thrombin and eventually prevents the formation of cross-linked fibrin clots. Rivaroxaban does not affect existing thrombin levels.
CAS:
366789-02-8
Formula:
C19H18ClN3O5S
Molecular Weight:
435.88
Pathway:
Metabolism; Proteases/Proteasome
Purity:
0.9969
SMILES:
Clc1ccc(s1)C(=O)NC[C@H]1CN(C(=O)O1)c1ccc(cc1)N1CCOCC1=O
Target:
Factor Xa; Thrombin

References

1. Perzborn E, et al. J Thromb Haemost, 2005, 3(3), 514?521. 2. Gnoth MJ, et al. J Pharmacol Exp Ther, 2011, 338(1), 372-380. 3. Weinz C, et al. Xenobiotica, 2005, 35(9), 891-910.